Head and Neck Squamous Cell Carcinoma Clinical Trials

65 studies are recruiting for head and neck squamous cell carcinoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

   The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P02 monotherapy in adult patients with selected squamous solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Foundation for Medical Education and Research - Mayo Cl, Scottsdale, Arizona

   Locations

   41 in total

   Run by

   Alentis Therapeutics AG

   See if you can join NCT06747585 on ClinicalTrials.gov

2. Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

   Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. Head and Neck Squamous Cell Carcinoma (HNSCC) is a solid tumor, a disease in which ca…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope National Medical Center /ID# 276272, Duarte, California

   Locations

   48 in total

   Run by

   AbbVie

   See if you can join NCT05005403 on ClinicalTrials.gov

3. Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC

   This research study is evaluating effectiveness and safety of a combination of immunotherapy drug, pembrolizumab, with chemotherapy, as a possible treatment before and after surgery for squamous cell carcinoma of the head and neck (HNSCC). The combination of pembrolizumab and chemotherapy will be g…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Dana-Farber Cancer Institute, Boston, Massachusetts

   Locations

   2 in total

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT05726370 on ClinicalTrials.gov

4. A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

   This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid tumor types that express B7-H3 and PTK7.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute at HealthONE, Denver, Colorado

   Locations

   15 in total

   Run by

   IDEAYA Biosciences

   See if you can join NCT07503808 on ClinicalTrials.gov

5. Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study.

   To learn if OCSCC patients can be safely given methylnaltrexone for 2 weeks before surgery.

   Stage

   Phase 4

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT06162377 on ClinicalTrials.gov

6. A Study of the Use of Fat Flap Reconstruction to Reduce Neck Injury After Cancer Treatment

   The purpose of this study is to find out whether the fat ALT flap procedure is a safe and practical option for reducing neck morbidity in HNSCC patients following cancer treatment of the neck. Neck morbidity after radiation therapy and surgery includes difficulty swallowing, neck or shoulder pain, …

   Stage

   Not phased

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT05889091 on ClinicalTrials.gov

7. A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

   This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Site 164, Mobile, Alabama

   Locations

   205 in total

   Run by

   Merus B.V.

   See if you can join NCT06525220 on ClinicalTrials.gov

8. A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer

   By doing this study, the research team would like to learn if using a blood test that measures the amount of tumor DNA in blood can help guide how to use chemotherapy combined with immunotherapy for individuals with head and neck cancer. Using this blood test, the research team hopes to learn if in…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Chicago Comprehensive Cancer Center, Chicago, Illinois

   Run by

   University of Chicago

   See if you can join NCT05420948 on ClinicalTrials.gov

9. High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

   This phase III trial tests if gabapentin can prevent the need for opiate pain medication for mouth sores (oral mucositis) in patients undergoing treatment with chemotherapy and radiation for squamous cell carcinoma of the head and neck region. Oral mucositis is a common side effect of radiation tre…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Arizona Center for Cancer Care - Gilbert, Gilbert, Arizona

   Locations

   200 in total

   Run by

   Alliance for Clinical Trials in Oncology

   See if you can join NCT06992427 on ClinicalTrials.gov

10. Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma

    This Phase I, single-institution, open-label study will evaluate the safety, tolerability, and diagnostic performance of [18F]NOTA-ABY030 PET/CT in patients with head and neck squamous cell carcinoma (HNSCC) who present with indeterminate lesions on standard imaging. The investigational agent is a …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Vanderbilt University Medical Center, Nashville, Tennessee

    Run by

    Vanderbilt-Ingram Cancer Center

    See if you can join NCT07217028 on ClinicalTrials.gov

11. (89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma

    The goal of this phase I clinical trial is to evaluate the usefulness of an imaging test (zirconium Zr89 panitumumab [89Zr panitumumab]) with positron emission tomography (PET)/computed tomography (CT) for diagnosing the spread of disease from where it first started (primary site) to other places i…

    Stage

    Phase 1

    Ages

    19 and older

    Site

    Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee

    Run by

    Eben Rosenthal

    See if you can join NCT05747625 on ClinicalTrials.gov

12. Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC

    The primary goal of this study is to examine whether recurrence of HPV-associated OPSCC can be predicted by two factors: 1) mutations in genes called TRAF3 and CYLD, and 2) measurements of circulating HPV DNA in blood plasma. The study will also investigate whether HPV integration is associated wit…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

    Locations

    3 in total

    Run by

    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT04564989 on ClinicalTrials.gov

13. A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)

    This is a non-randomized, open-label, single-center, safety and imaging feasibility study of Pegsitacianine, an intraoperative fluorescence imaging agent.

    Stage

    Phase 2

    Ages

    18 to 99

    Site

    University of Texas Southwestern Medical Center, Dallas, Texas

    Run by

    University of Texas Southwestern Medical Center

    See if you can join NCT05576974 on ClinicalTrials.gov

14. A Study of VET3-TGI in Patients With Solid Tumors

    VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injection into tumor(s) (called an intratumoral injection) or whe…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    USC/Norris Comprehensive Cancer Center, Los Angeles, California

    Locations

    7 in total

    Run by

    KaliVir Immunotherapeutics

    See if you can join NCT06444815 on ClinicalTrials.gov

15. This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

    This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Toripalimab in patients with advanced solid tumors who have exhausted all standard therapy available or are intolerant of the same.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Dana Farber Cancer Institute, Boston, Massachusetts

    Locations

    3 in total

    Run by

    Zumutor Biologics Inc.

    See if you can join NCT06451497 on ClinicalTrials.gov

16. Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

    This phase I trial studies the side effects and best dose of modified immune cells (IL13Ralpha2 CAR T cells) after a chemotherapy conditioning regimen for the treatment of patients with stage IIIC or IV melanoma or solid tumors that have spread to other places in the body (metastatic). The study ag…

    Stage

    Phase 1

    Ages

    18 to 75

    Site

    City of Hope, Duarte, California

    Locations

    3 in total

    Run by

    Anusha Kalbasi

    See if you can join NCT04119024 on ClinicalTrials.gov

17. Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer

    This phase I trial tests the safety and effectiveness of indium In 111 panitumumab (111In-panitumumab) for identifying the first lymph nodes to which cancer has spread from the primary tumor (sentinel lymph nodes) in patients with head and neck squamous cell carcinoma (HNSCC) undergoing surgery. Th…

    Stage

    Phase 1

    Ages

    19 and older

    Site

    Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee

    Run by

    Vanderbilt-Ingram Cancer Center

    See if you can join NCT05901545 on ClinicalTrials.gov

18. Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer

    The purpose of this study is to evaluate the safety, tolerability and maximum tolerated dose of tislelizumab in combination with pamiparib plus chemoradiotherapy (chemotherapy and radiation) in individuals with recurrent head and neck cancer, which means that the person's cancer has come back after…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Chicago, Chicago, Illinois

    Run by

    University of Chicago

    See if you can join NCT05526924 on ClinicalTrials.gov

19. Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).

    This research is being done to see if it is safe to give investigational combination of study drugs (Pembrolizumab and IO102-103) before surgery to people with surgically resectable (removable) newly diagnosed or recurrent metastatic SCCHN. This will be done by watching participants closely for pos…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Johns Hopkins University, Baltimore, Maryland

    Locations

    5 in total

    Run by

    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    See if you can join NCT05977907 on ClinicalTrials.gov

20. Virtual Reality 3D-Surgery Modeling to Enhance Head and Neck Cancer Surgery Quality

    This clinical trial studies the use of virtual reality technology and three dimensional surgery (3D-surgery) modeling to enhance current treatments in head and neck cancer surgery. Virtual reality 3D-surgery modeling may improve quality of surgical planning and interdisciplinary communication betwe…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania

    Run by

    Thomas Jefferson University

    See if you can join NCT05031910 on ClinicalTrials.gov

21. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

    Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    HonorHealth Research Institute, Scottsdale, Arizona

    Locations

    21 in total

    Run by

    Clasp Therapeutics, Inc.

    See if you can join NCT06778863 on ClinicalTrials.gov

22. Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors

    This study is a first in human Phase 1 study that involves patients with a type of cancer called HER2 (Human Epidermal Growth Factor Receptor 2) positive cancer. This study asks patients to volunteer to take part in a research study investigating the safety and efficacy of using special immune cell…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Baylor St. Luke's Medical Center, Houston, Texas

    Run by

    Baylor College of Medicine

    See if you can join NCT03740256 on ClinicalTrials.gov

23. Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

    The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Beverly Hills Cancer Center, Beverly Hills, California

    Locations

    39 in total

    Run by

    SystImmune Inc.

    See if you can join NCT05983432 on ClinicalTrials.gov

24. A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

    A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Dren Investigational Site, Denver, Colorado

    Locations

    10 in total

    Run by

    Dren Bio

    See if you can join NCT06999187 on ClinicalTrials.gov

25. Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma

    This pilot clinical study will investigate if Zirconium-89 (89Zr) panitumumab- Positron Emission Tomography/ Magnetic Resonance Imaging (PET/MRI) imaging can more accurately determine size and location of primary tumors compared to standard of care Fludeoxyglucose (18F-FDG) -PET/MRI in newly diagno…

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    UAB, Birmingham, Alabama

    Run by

    University of Alabama at Birmingham

    See if you can join NCT05183048 on ClinicalTrials.gov